South Korean AI company Lunit has tied up with its investor, Guardant Health, for AI integration.
Under the partnership, Lunit will integrate its PD-L1 scoring algorithm into Guardant's cancer biomarker detection workflow in the Guardant360 TissueNextTM PD-L1 test for non-small cell lung cancer (NSCLC).
Lunit SCOPE PD-L1, a CE-marked AI solution, detects and analyses PD-L1, a type of cancer...
AI startup Lunit from South Korea has bagged $26 million in a Series C Tranche B funding round. The investment came from Guardant Health, a Nasdaq-listed precision oncology firm.
WHAT IT DOES
Founded in 2013, Lunit develops AI software in the oncology space. Its solutions are designed to discover cancer and predict cancer treatment outcomes.
One of its tech solutions, tissue analysis platform...
